Downregulated miR-33b is a novel predictor associated with disease progression and poor prognosis in multiple myeloma. Issue 7 (July 2015)

• Record Type: Journal Article
• Authors: Li, Fei; Hao, Mu; Feng, Xiaoyan; Zang, Meirong; Qin, Yu; Yi, Shuhua; Li, Zengjun; Xu, Yan; Zhou, Lili; Sui, Weiwei; Deng, Shuhui; Zou, Dehui; Zhan, Fenghuang; Qiu, Lugui
• Is Part Of: Leukemia research. Volume 39:Issue 7(2015:Jul.)
• Page Start: 793
• Page End: 799
• Publication Date: 2015-07
• Subjects: Leukemia -- Periodicals; Leukemia -- Periodicals; Leucémie -- Périodiques; Leukemia; Periodicals; Electronic journals; Electronic journals; 616.9941905
• DOI: 10.1016/j.leukres.2015.04.010
• Languages: English
• ISSNs: 0145-2126

Abstract

<abstract abstract-type="author-highlights" id="abs0005"> <title id="sect0005">Highlights</title> <sec> <p id="spar0005"> <list id="lis0005"> <list-item id="lsti0005"> <label></label> <p id="par0005">MiR-33b is obviously downregulated in newly diagnosed and relapsed MM patients.</p> </list-item> <list-item id="lsti0010"> <label></label> <p id="par0010">Downregulated miR-33b is usually in MM patients with genetic abnormalities.</p> </list-item> <list-item id="lsti0015"> <label></label> <p id="par0015">Patients with miR-33b low expression have significantly shortened PFS and OS.</p> </list-item> <list-item id="lsti0020"> <label></label> <p id="par0020">Downregulated MiR-33b might be associated with bortezomib-based treatment in MM.</p> </list-item> </list> </p> </sec> </abstract>